Medicalgorithmics, a medtech company listed on the Warsaw Stock Exchange, Poland, included in the sWIG80 index, a provider of technological solutions for cardiology, has signed an agreement with another U.S.-based Independent Diagnostic Testing Facility (IDTF). The agreement includes the utilization of the company’s AI software, algorithms, and platform. Once integrated, this will allow for the analysis of ECG data, connecting the American partner’s devices with Medicalgorithmics’ advanced software for heart disease diagnostics. This marks the second contract Medicalgorithmics has entered into with a U.S. IDTF since announcing their new strategy in June.
Medicalgorithmics wins another tender for the delivery of remote cardiac diagnostics solutions in Poland
Medicalgorithmics, a global medtech company, has won a tender worth over PLN 800.000 gross (approximately $200.000 gross) for the delivery of 50 cardiac monitoring devices (PocketECG IV) along with the cutting-edge software and algorithms for ECG signal analysis to a public medical facility in Białystok (Poland). Medicalgorithmics was the only bidder in the tender.
Medicalgorithmics has signed annex to its agreement with Canadian company m-Health Solutions Inc. owned by ELNA Medical Group Company, which entails the delivery of the latest generation PocketECG IV devices. The plan also includes the integration of Medicalgorithmics’ software and algorithms with holter wearable devices from dms-service llc that m-Health Solutions Inc. offers, facilitating data analysis of EKG and improving cardiac diagnostics for the Canadian company.
Medicalgorithmics, a medtech company listed on the Warsaw Stock Exchange, has signed a letter of intent with Cardiologix for the delivery of its PocketECG IV system for detecting heart arrhythmias in the US market. It is planned that the Polish technology company will provide heart monitoring devices along with an artificial intelligence diagnostic system for cardiac diagnostics.
Medicalgorithmics has been selected by CRO company Simbec-Orion as a provider of remote diagnostic solutions for a clinical trial commissioned by biotechnology company Molecure. The clinical trial, which will involve approximately 90 patients at research centers in Europe and the USA, will utilize the PocketECG IV device and the cloud-based PC Client solution.